Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia

Phase 1

Withdrawn

Conditions: Oral Leukoplakia

Interventions: Drug: 5-fluorouracil

First Posted Date: 2022-08-17

Last Posted Date: 2022-09-22

Lead Sponsor: University of California, San Francisco

Registration Number: NCT05505539

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: HAIC(FOLFOX)
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil
Drug: Toripalimab
Drug: Donafenib

First Posted Date: 2022-08-09

Last Posted Date: 2022-08-18

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 93

Registration Number: NCT05493332

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Phase 2

Recruiting

Conditions: HPV
Oropharyngeal Carcinoma
Human Papilloma Virus
Oropharyngeal Cancer
Throat Cancer

Interventions: Diagnostic Test: 18 F-FMISO PET/CT
Radiation: Radiation
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-fluorouracil

First Posted Date: 2022-08-08

Last Posted Date: 2024-05-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 121

Registration Number: NCT05491512

Locations: 🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2

Recruiting

Conditions: Endometrial Cancer
Gastric Cancer
Metastatic Castration-resistant Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Urothelial Cancer
Biliary Tract Cancer

Interventions: Drug: Datopotamab deruxtecan (Dato-DXd)
Drug: 5-Fluorouracil
Drug: Prednisone/ prednisolone
Drug: Capecitabine
Drug: Volrustomig
Drug: Rilvegostomig
Drug: Carboplatin
Drug: Bevacizumab
Drug: Cisplatin
Drug: Leucovorin LV

First Posted Date: 2022-08-05

Last Posted Date: 2024-11-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 582

Registration Number: NCT05489211

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

PT886 for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma
Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: PT886
Drug: Paclitaxel
Drug: KEYTRUDA® (pembrolizumab)
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Abraxane
Drug: Leucovorin
Drug: FOLFIRINOX
Drug: Fluorouracil
Drug: Capecitabine

First Posted Date: 2022-08-01

Last Posted Date: 2024-11-22

Lead Sponsor: Phanes Therapeutics

Target Recruit Count: 135

Registration Number: NCT05482893

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States
🇺🇸
Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, United States

and more 3 locations

mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Advanced/Metastatic Colorectal Cancer

Interventions: Drug: Dalpiciclib
Drug: Oxaliplatin injection
Drug: Calcium folinate
Drug: 5-fluorouracil

First Posted Date: 2022-07-29

Last Posted Date: 2023-02-28

Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Target Recruit Count: 18

Registration Number: NCT05480280

Locations: 🇨🇳
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma
Locally Advanced Carcinoma

Interventions: Drug: Tislelizumab
Drug: 5-FU
Drug: cis Platinum

First Posted Date: 2022-07-21

Last Posted Date: 2022-07-21

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 17

Registration Number: NCT05469061

Locations: 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China

A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC

Phase 2

Not yet recruiting

Conditions: Chemo-radiotherapy
Nasopharyngeal Carcinoma
TNF

Interventions: Drug: 5-fu
Drug: Cisplatin
Radiation: Radiotherapy
Drug: Placebo
Drug: TNF

First Posted Date: 2022-06-27

Last Posted Date: 2022-06-27

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 172

Registration Number: NCT05433597

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

Phase 1

Recruiting

Conditions: Locally Advanced Rectal Cancer

Interventions: Radiation: Accelerated Radiation Therapy
Radiation: Intensity-modulated radiation therapy
Drug: 5-fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2022-06-09

Last Posted Date: 2023-10-02

Lead Sponsor: University of Miami

Target Recruit Count: 25

Registration Number: NCT05412082

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

Phase 1

Active, not recruiting

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Irinotecan liposome injection
Drug: Folinic Acid
Drug: 5-Fluorouracil

First Posted Date: 2022-05-20

Last Posted Date: 2024-12-27

Lead Sponsor: Ipsen

Target Recruit Count: 177

Registration Number: NCT05383352

Locations: 🇫🇷
Institut BERGONIE Centre de Lutte Contre le Cancer, Bordeaux, France
🇦🇺
Flinders Medical Centre, Bedford Park, Australia
🇦🇺
Peninsula and Southeast Oncology - Frankston Private Hospital, Frankston, Australia

and more 33 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy